Blog
In vivo CAR-T Insights Series (4) — The Role of mRNA in In vivo CAR-T
Release Time：
2025-12-03 16:06
In vivo CAR-T is redefining how we approach adoptive cell therapy by enabling CAR-T generation directly within the patient. A key question arises: why use mRNA instead of DNA or viral vectors?
🔎 Why mRNA?
Unlike DNA or viral vectors, mRNA allows transient yet effective expression of CAR constructs without the risk of genomic integration. This makes it a safer and more controllable option for in vivo applications.
✅ Advantages of mRNA
- Controlled expression – transient CAR expression provides safety and dosing flexibility
- No genomic integration risk – reduces concerns of insertional mutagenesis
- Rapid production – cell-free manufacturing accelerates preclinical and clinical timelines
⚠️ Limitations to overcome
- Limited stability in vivo – prone to degradation in biological environments
- Requires optimized delivery – effective lipid nanoparticle (LNP) or antibody-LNP systems are essential for targeted, durable expression
🌟 Unique value of mRNA in in vivo therapy
mRNA brings a balance of safety, speed, and flexibility that makes it a cornerstone in the development of in vivo CAR-T strategies. Its transient nature not only improves safety but also opens the door for tunable therapies adaptable to different clinical needs.
Levostar’s In vivo CAR-T Solutions
From mRNA synthesis to LNP delivery, Levostar empowers your in vivo CAR-T research with speed and precision. Our flexible antibody conjugation options further expand targeting possibilities, driving innovation in next-generation cell therapy.
Let’s accelerate the future of cell therapy — directly inside the body.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898